Frazier Life Sciences Management, L.P. Arcutis Biotherapeutics, Inc. Transaction History
Frazier Life Sciences Management, L.P.
- $1.86 Billion
- Q3 2024
A detailed history of Frazier Life Sciences Management, L.P. transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Frazier Life Sciences Management, L.P. holds 8,785,284 shares of ARQT stock, worth $102 Million. This represents 4.4% of its overall portfolio holdings.
Number of Shares
8,785,284
Previous 8,785,284
-0.0%
Holding current value
$102 Million
Previous $81.7 Million
-0.0%
% of portfolio
4.4%
Previous 4.82%
Shares
4 transactions
Others Institutions Holding ARQT
# of Institutions
204Shares Held
129MCall Options Held
738KPut Options Held
82K-
Jennison Associates LLC12.3MShares$143 Million0.11% of portfolio
-
Rubric Capital Management LP New York, NY11MShares$127 Million2.84% of portfolio
-
Suvretta Capital Management, LLC New York, NY10.7MShares$124 Million3.92% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$99.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.96MShares$80.7 Million0.0% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $698M
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...